Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/03/24	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/01/24	CoTec Holdings Outlines Key Targets For 2024	MT
03/01/24	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/10/23	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/10/23	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/10/23	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/09/23	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/09/23	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/06/23	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
31/08/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	+0.25%	+2.41%	+49.51%	+157.55%	42.57B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%

Employees

Sector